Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
Kuroda J, Kobayashi T, Tsutsumi Y, Yamamoto M, Ohshiro M, Sasaki N, Shimura Y, Mizutani S, Nagoshi H, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Taniwaki M. Kuroda J, et al. Among authors: mizutani s. Int J Hematol. 2010 Nov;92(4):669-72. doi: 10.1007/s12185-010-0709-3. Epub 2010 Oct 27. Int J Hematol. 2010. PMID: 20978877 No abstract available.
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Kiyota M, et al. Among authors: mizutani s. Int J Hematol. 2012 May;95(5):516-26. doi: 10.1007/s12185-012-1035-8. Epub 2012 Mar 17. Int J Hematol. 2012. PMID: 22426624
Comprehensive cytogenetic study of primary cutaneous gamma-delta T-cell lymphoma by means of spectral karyotyping and genome-wide single nucleotide polymorphism array.
Yamamoto-Sugitani M, Kuroda J, Shimura Y, Nagoshi H, Chinen Y, Ohshiro M, Mizutani S, Kiyota M, Nakayama R, Kobayashi T, Uchiyama H, Matsumoto Y, Horiike S, Taniwaki M. Yamamoto-Sugitani M, et al. Among authors: mizutani s. Cancer Genet. 2012 Sep;205(9):459-64. doi: 10.1016/j.cancergen.2012.05.006. Epub 2012 Jul 21. Cancer Genet. 2012. PMID: 22819381
Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
Kobayashi T, Tsutsumi Y, Sakamoto N, Nagoshi H, Yamamoto-Sugitani M, Shimura Y, Mizutani S, Matsumoto Y, Nishida K, Horiike S, Asano N, Nakamura S, Kuroda J, Taniwaki M. Kobayashi T, et al. Among authors: mizutani s. Jpn J Clin Oncol. 2012 Nov;42(11):1035-42. doi: 10.1093/jjco/hys148. Epub 2012 Sep 14. Jpn J Clin Oncol. 2012. PMID: 22984125
RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.
Shimura Y, Kuroda J, Ri M, Nagoshi H, Yamamoto-Sugitani M, Kobayashi T, Kiyota M, Nakayama R, Mizutani S, Chinen Y, Sakamoto N, Matsumoto Y, Horiike S, Shiotsu Y, Iida S, Taniwaki M. Shimura Y, et al. Among authors: mizutani s. Mol Cancer Ther. 2012 Dec;11(12):2600-9. doi: 10.1158/1535-7163.MCT-12-0605. Epub 2012 Sep 25. Mol Cancer Ther. 2012. PMID: 23012246
Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
Shimura Y, Kuroda J, Uchiyama H, Kawata-Iida E, Tsutsumi Y, Nagoshi H, Mizutani S, Yamamoto-Sugitani M, Matsumoto Y, Kobayashi T, Horiike S, Shimazaki C, Kaneko H, Kobayashi Y, Taniwaki M. Shimura Y, et al. Among authors: mizutani s. J Clin Apher. 2013 Oct;28(5):368-73. doi: 10.1002/jca.21283. Epub 2013 Jun 27. J Clin Apher. 2013. PMID: 23804501
1,137 results